Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 6

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Myeloid 6

Conditions

Polycythemia Vera 6Thrombocythemia, Essential 5Carcinoma, Hepatocellular 4Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Leukemia 2Hepatitis C, Chronic 2Carcinoma, Squamous Cell 2Skin Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Influenza, Human 1Infections 1Hepatitis C 1Hepatitis B, Chronic 1Hemangiosarcoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Blast Crisis 1

Interventions

fludarabine phosphate 24Peripheral Blood Stem Cell Transplantation 21Cyclophosphamide 21Busulfan 19Whole-Body Irradiation 15Tacrolimus 15Mycophenolic Acid 13Methotrexate 12ruxolitinib 11Cyclosporine 10Antilymphocyte Serum 10fludarabine 8Melphalan 7peginterferon alfa-2a 6Aspirin 6Filgrastim 5Stem Cell Transplantation 4Radiotherapy 4Imatinib Mesylate 4Hydroxyurea 4Flow Cytometry 4Etoposide 4Decitabine 4Biopsy 4Azacitidine 4Thiotepa 3Surveys and Questionnaires 3Prednisone 3Methylprednisolone 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Polycythemia Vera × peginterferon alfa-2a × Clear all
NCT00452023 2024-12-11

Pegasys® in Patients With Myeloproliferative Diseases

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential

NCT01387763 2022-04-27

DALIAH

Odense University Hospital

Phase 3 Completed
202 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT01259817 2017-01-11

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
135 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT00241241 2015-10-21

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

PV-Nord

Phase 2 Completed
40 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡